BiotechTube

Ridinilazole + Vancomycin

Phase 3Completed
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Clostridioides Difficile Infection

Conditions

Clostridioides Difficile Infection

Trial Timeline

Jan 28, 2019 → Nov 17, 2021

NCT ID
NCT03595553

About Ridinilazole + Vancomycin

Ridinilazole + Vancomycin is a phase 3 stage product being developed by Summit Therapeutics for Clostridioides Difficile Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT03595553. Target conditions include Clostridioides Difficile Infection.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT04802837Phase 3Terminated
NCT03595553Phase 3Completed

Competing Products

7 competing products in Clostridioides Difficile Infection

See all competitors
ProductCompanyStageHype Score
AZD5148AstraZenecaPhase 2
52
AZD5148 + PlaceboAstraZenecaPhase 1
33
C.difficile vaccinePfizerPhase 3
76
Ridinilazole + VancomycinSummit TherapeuticsPhase 3
74
REC-3964Recursion PharmaceuticalsPhase 2
47
SER-109Seres TherapeuticsPre-clinical
15
SER-109Seres TherapeuticsPhase 3
69

Other Products from Summit Therapeutics

Ridinilazole + VancomycinPhase 3
74
Drug: Ivonescimab Injection + Drug: Bevacizumab InjectionPhase 3
74
Ivonescimab Injection + Pembrolizumab InjectionPhase 3
74
Ivonescimab Injection + Pembrolizumab InjectionPhase 3
74
IvonescimabPhase 2
49